Predicting the intrinsic insensitivity of some ATC to CDK4/6i might be important because, like RB-deficient tumors in other cancers such as small cell lung cancers (SCLC), they might respond particularly well to genotoxic chemotherapy (89, 90). This evidence concerns the gene RB1 and small cell lung carcinoma.